Cartesian Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Cartesian Therapeutics, Inc. (RNAC) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-77.42-219.7135.38-25.69-68.88-55.35-65.34
Depreciation & Amortization1.150.841.291.251.861.870.98
Deferred Income Tax0.29-19.000.000.000.000.000.00
Stock Based Compensation6.5822.5211.197.720.000.000.00
Change in Working Capital-5.794.97-60.38-48.1985.00-4.48-0.78
Change in Accounts Receivable7.980.910.16-2.690.000.000.00
Change in Accounts Payable-2.932.830.09-0.220.000.000.00
Change in Other Working Capital39.34-4.034.68-0.390.000.000.00
Other Operating Activities39.34139.10-18.594.4716.496.420.45
Net Cash from Operating Activities-23.67-51.16-31.63-60.3834.88-51.44-59.16
Investing Activities
Capital Expenditures-9.09-0.21-1.20-1.090.820.05-0.79
Acquisitions0.356.560.000.000.000.000.00
Purchases of Investments0.0028.25-13.80-16.060.000.000.00
Sales/Maturities of Investments0.0028.2519.70-16.060.000.1526.06
Net Cash from Investing Activities-8.7434.61-15.00-17.14-0.740.2325.27
Financing Activities
Debt Repayment0.00-27.460.000.00-19.31-2.800.00
Common Stock Issued124.440.2339.3352.9010.450.030.00
Common Stock Repurchased0.00-6.170.000.000.000.000.00
Other Financing Activities-0.07-6.17-0.110.00-0.340.000.00
Net Cash from Financing Activities168.43-13.1539.2252.9014.43105.040.70
Summary
Effect of Forex Changes on Cash-0.02-0.050.020.00-0.060.03-0.15
Net Change in Cash136.01-29.75-7.40-24.6348.5153.87-33.19
Cash at Beginning of Period78.29108.04115.44140.0691.5537.6871.03
Cash at End of Period214.2878.29108.04115.44140.0637.6837.68
Free Cash Flow-32.77-51.37-32.83-61.4734.14-51.36-60.05
Supplemental Disclosures
Interest Paid0.001.852.252.001.021.221.13